Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Plasmacytoma 1Neoplasm Metastasis 1Homologous Recombination Deficient Solid Tumors 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1

Interventions

Amifostine 4Cisplatin 3Voriconazole 2Radiotherapy 2Paclitaxel 2Methotrexate 2Drug Therapy 2selinexor 1sargramostim 1pazopanib 1lometrexol 1icotinib 1glucarpidase 1camrelizumab 1bismuth tripotassium dicitrate 1apatinib 1Telbivudine 1Surgical Procedures, Operative 1Pregabalin 1Pharmaceutical Preparations 1Ofloxacin 1Nivolumab 1Metronidazole 1Levofloxacin 1Imatinib Mesylate 1Hyperthermic Intraperitoneal Chemotherapy 1Gefitinib 1Folic Acid 1Etoposide 1Esomeprazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Drug-Related Side Effects and Adverse Reactions × Drug Combinations × Clear all
NCT04138381 2023-03-27

SeliGIST

Grupo Espanol de Investigacion en Sarcomas

Phase 1/2 Unknown
30 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡